Form 4: Kymera Therapeutics Director Sells Shares Under 10b5-1 Plan

Kymera Therapeutics Director Bruce Booth reported the sale of common stock valued at over $2.5 million through a pre-arranged 10b5-1 trading plan.

Summary

• Bruce Booth, a Director at Kymera Therapeutics, Inc., reported transactions involving the sale of common stock on June 26 and June 29, 2026.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• The total reported sales amount to approximately $2.5 million, with individual transaction prices ranging from $105.015 to $119.035.
• The shares sold were held indirectly through entities such as Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with Booth disclaiming beneficial ownership beyond his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-established 10b5-1 plan, which is a standard and often necessary tool for insiders to manage their stock holdings.

Negatives

• Director Bruce Booth sold a significant number of shares, indicating a reduction in his direct beneficial ownership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives and directors to diversify holdings or manage personal finances in a pre-determined manner, mitigating concerns about timing the market. However, the volume and timing of such sales can still be a point of interest for investors.

Stakeholder Impact

• Shareholders may observe the director's stock sales, but the 10b5-1 plan structure suggests it is not necessarily a reflection of negative company outlook.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Bruce Booth, Director Transactions